每经AI快讯,有投资者在投资者互动平台提问:公司在2026年2月取得辅酶Q10原料药生产资质后,当前医药级产品送样、客户验证、订单洽谈进展如何?是否已有意向订单或框架协议?预计何时能实现规模化销售并贡献收入?医药级产品单价较食品级高多少?拓新药业(301089.SZ)4月10日在投资者互动平台表示,公司辅酶Q10原料产品当前以食品级销售为主,正积极布局医药级市场拓展。(文章来源:每日经济新闻) ...
Source Link每经AI快讯,有投资者在投资者互动平台提问:公司在2026年2月取得辅酶Q10原料药生产资质后,当前医药级产品送样、客户验证、订单洽谈进展如何?是否已有意向订单或框架协议?预计何时能实现规模化销售并贡献收入?医药级产品单价较食品级高多少?拓新药业(301089.SZ)4月10日在投资者互动平台表示,公司辅酶Q10原料产品当前以食品级销售为主,正积极布局医药级市场拓展。(文章来源:每日经济新闻) ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.